Show simple item record

dc.contributor.authorMarcy, Olivier*
dc.contributor.authorLaureillard, Didier*
dc.contributor.authorMadec, Yoann*
dc.contributor.authorChan, Sarin*
dc.contributor.authorMayaud, Charles*
dc.contributor.authorBorand, Laurence*
dc.contributor.authorPrak, Narom*
dc.contributor.authorKim, Chindamony*
dc.contributor.authorLak, Kim Khemarin*
dc.contributor.authorHak, Chanroeurn*
dc.contributor.authorDim, Bunnet*
dc.contributor.authorSok, Thim*
dc.contributor.authorDelfraissy, Jean-François*
dc.contributor.authorGoldfeld, Anne E*
dc.contributor.authorBlanc, François-Xavier*
dc.date.accessioned2014-12-11T22:47:59Z
dc.date.available2014-12-11T22:47:59Z
dc.date.issued2014-08
dc.identifier.citationCauses and determinants of mortality in HIV-infected adults with tuberculosis: an analysis from the CAMELIA ANRS 1295-CIPRA KH001 randomized trial. 2014, 59 (3):435-45 Clin. Infect. Dis.en_GB
dc.identifier.issn1537-6591
dc.identifier.pmid24759827
dc.identifier.doi10.1093/cid/ciu283
dc.identifier.urihttp://hdl.handle.net/10144/337112
dc.description.abstractShortening the interval between antituberculosis treatment onset and initiation of antiretroviral therapy (ART) reduces mortality in severely immunocompromised human immunodeficiency virus (HIV)-infected patients with tuberculosis. A better understanding of causes and determinants of death may lead to new strategies to further enhance survival.
dc.language.isoenen
dc.publisherOxford University Pressen_GB
dc.rightsArchived on this site with kind permission of Oxford University Press and thanks to Clinical Infectious Diseases : an official publication of the Infectious Diseases Society of Americaen_GB
dc.titleCauses and determinants of mortality in HIV-infected adults with tuberculosis: an analysis from the CAMELIA ANRS 1295-CIPRA KH001 randomized trialen
dc.identifier.journalClinical Infectious Diseases : an official publication of the Infectious Diseases Society of Americaen_GB
refterms.dateFOA2019-03-04T11:39:44Z
html.description.abstractShortening the interval between antituberculosis treatment onset and initiation of antiretroviral therapy (ART) reduces mortality in severely immunocompromised human immunodeficiency virus (HIV)-infected patients with tuberculosis. A better understanding of causes and determinants of death may lead to new strategies to further enhance survival.


Files in this item

Thumbnail
Name:
Marcy O - 2014 - Causes and ...
Size:
227.6Kb
Format:
PDF
Description:
Main article

This item appears in the following Collection(s)

Show simple item record